deoxycholic acid · Abbvie · NDA 206333
Kybella
Earliest generic entry, as listed
17 Feb 2032
Blocked by patent: US 12161653. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 14 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12161653 | use U-1940 · sets the listed date | 17 Feb 2032 |
| US 10500214 | drug product | 2 Mar 2030 |
| US 8101593 | drug product | 2 Mar 2030 |
| US 8367649 | drug product | 2 Mar 2030 |
| US 8653058 | drug product | 2 Mar 2030 |
| US 8242294 | drug substance | 16 May 2028 |
| US 8461140 | drug product | 21 Feb 2028 |
| US 8546367 | drug product, use U-1690 | 21 Feb 2028 |
| US 8883770 | drug product | 21 Feb 2028 |
| US 9522155 | drug product, use U-1940 | 21 Feb 2028 |
| US 9636349 | use U-1940 | 21 Feb 2028 |
| US 9949986 | use U-1940 | 21 Feb 2028 |
| US 7622130 | use U-1690 | 10 Dec 2027 |
| US 7754230 | use U-1690 | 10 Dec 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206333 · 001 · RLD | solution, subcutaneous | 20MG/2ML (10MG/ML) | 17 Feb 2032 |